Doctors have long worried that the frailest older patients, the ones with the least physical reserve to handle a new medication, might not get the same benefit from popular weight-loss drugs as healthier patients do, or might be put at greater risk by them. A new analysis of one of the largest cardiovascular trials of a GLP-1 drug pushes back on that concern. Looking specifically at how frailty status changed the drug’s effect, researchers found the heart-protective benefit held up across the board, and by some measures was strongest in the patients who started out the most frail.
The analysis draws on data originally collected for a trial designed to test whether the drug could prevent heart attacks and strokes, not just help patients lose weight.
Revisiting the SELECT Trial Through a Frailty Lens
The new work is a post hoc analysis of the SELECT trial, a randomized study that originally enrolled more than 17,000 adults with established cardiovascular disease and overweight or obesity, but without diabetes, to test whether semaglutide could reduce cardiovascular death, heart attack, and stroke. The analysis published in JAMA Cardiology reclassified that same patient population by frailty status, a measure that accounts for factors like muscle strength, mobility, and overall physical reserve rather than age alone, and then re-examined whether the drug’s cardiovascular benefit changed depending on how frail a patient was going in.
The Original Trial’s Core Numbers
SELECT enrolled 17,604 adults across 41 countries, randomly assigning 8,803 to weekly 2.4-milligram semaglutide injections and 8,801 to placebo, then following them for a mean of nearly three and a half years of treatment and just under four years of total follow-up. A primary cardiovascular event, meaning cardiovascular death, a nonfatal heart attack, or a nonfatal stroke, occurred in 6.5% of the semaglutide group compared with 8.0% of the placebo group, a 20% relative risk reduction that was statistically decisive. That original result, published in the New England Journal of Medicine by lead investigator A. Michael Lincoff and colleagues, is what the new frailty analysis re-examined by layering a separate measurement onto the same patient records.
To do that, researchers built a 31-item frailty index that tallies accumulated health deficits, from mobility problems to chronic conditions, and sorted participants into three groups: not frail, with an index score at or below 0.210; more frail, scoring between 0.211 and 0.310; and most frail, above that threshold. Roughly 5,400 participants fell into the least frail group and just over 8,300 into the middle group, with the remainder in the most frail category. Semaglutide’s cardiovascular benefit held across all three groups, with hazard ratios ranging from 0.70 to 0.92, and the statistical test for whether frailty changed the drug’s effect came back well short of significance, meaning the benefit did not differ meaningfully by frailty group.
Why Frailty Status Matters More Than Age Alone
Frailty and chronological age are related but not the same thing. Two patients in their late seventies can have very different frailty profiles depending on how well they retain physical strength, balance, and independence, and clinicians increasingly treat frailty scores as a better predictor of how a patient will tolerate a new drug than birth year. That distinction matters for a trial population like SELECT’s, since the study’s original eligibility criteria, described in a separate analysis of the trial’s real-world applicability, focused on cardiovascular risk factors rather than frailty specifically, leaving open the question of how the drug would perform once that additional layer of vulnerability was accounted for.
The Benefit Held Regardless of Frailty Status
Across every frailty category examined, the drug’s cardiovascular benefit remained intact, meaning patients did not lose the heart-protective effect simply because they entered the trial more physically vulnerable. More notably, the benefit appeared strongest among the frailest patients in the analysis, the group clinicians might have expected to see the least benefit from, or the most risk from, an appetite-suppressing medication that can accelerate weight and muscle loss. That finding runs counter to a common clinical instinct that frail, older patients should be treated more cautiously with newer drugs simply because they have less physical margin to absorb side effects.
Weight Loss Drugs and the Muscle-Loss Concern
Part of the hesitation around prescribing GLP-1 drugs to frail older adults has centered on the fact that a meaningful share of the weight these drugs help patients lose comes from lean muscle mass, not just fat, a concern that is especially relevant for people who are already frail and have less muscle to spare. This new analysis does not resolve that muscle-loss question directly, since it focused on cardiovascular outcomes rather than body composition, but the fact that cardiovascular benefit held up despite that theoretical risk suggests the tradeoff, at least for heart outcomes, may favor treatment even in physically vulnerable patients. Other SELECT-trial analyses have separately looked at hospitalization outcomes; a related exploratory study found semaglutide was also associated with fewer hospital admissions and shorter hospital stays among trial participants with established cardiovascular disease.
What It Could Mean for Prescribing Decisions
Semaglutide, sold under brand names including Wegovy and Ozempic depending on the indication, has already become one of the most widely prescribed drugs in the country, and cardiologists have increasingly leaned on the original SELECT trial results to justify prescribing it for its heart benefits, not just for weight loss. A finding that frailty does not blunt that benefit removes one of the more common reasons a physician might hesitate to prescribe the drug to an older, more vulnerable patient. It does not eliminate the need for individualized judgment, since frailty analyses look at group-level trends rather than guaranteeing an outcome for any single patient, but it gives doctors treating frail older adults with cardiovascular disease more concrete evidence that age and physical vulnerability alone should not automatically rule the drug out.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Supplements now rank as the fifth-leading cause of death from liver disease.
- The NSA is again telling phone owners to switch off one location setting
- Four U.S. startups fired up their first small nuclear reactors, aiming to power AI data centers on-site
- 11 engines built to run well past 200,000 miles
